Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jorge Chahla

Sports Medicine Munster, IN Medical Doctor

NPI 1750891636 CMS profile 5699001

9200 Calumet Ave Ste 300, Munster, IN 46321

Open in the dashboard

General payments

$916,884

597 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$13,740

1 holding reported · through program year 2025

Research they led as principal investigator

$148,005 paid to institutions, not to them · program years 2020–2025

Through program year 2025, Jorge Chahla of Munster, IN is reported in the CMS Open Payments database as having received $916,884 across 597 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $148,005 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $13,740 across 1 holding.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $271,558 149
2024 General $111,097 77
2023 General $177,699 105
2022 General $84,277 44
2021 General $96,352 84
2020 General $87,041 54
2019 General $88,861 84
2025 Ownership $13,740 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jorge Chahla
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Jorge Chahla were reported at $271,558. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year Jorge Chahla Sports Medicine median Middle half National median
2019 $88,861 $1,176 $199–$4,249 $163
2020 $87,041 $708 $96–$2,890 $114
2021 $96,352 $1,213 $152–$3,994 $132
2022 $84,277 $1,230 $159–$3,998 $149
2023 $177,699 $584 $146–$2,836 $160
2024 $111,097 $628 $163–$3,168 $164
2025 $271,558 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Smith+Nephew, Inc. $844,174 474 payments
  2. Arthrex, Inc. $24,628 11 payments
  3. Linvatec Corporation $20,976 25 payments
  4. DePuy Synthes Products, Inc. $7,438 3 payments
  5. Synthes GmbH $7,310 7 payments
  6. Medwest Associates $4,334 8 payments
  7. Stryker Corporation $2,076 23 payments
  8. Medical Device Business Services, Inc. $1,672 15 payments
  9. Ossur Americas., Inc $1,590 5 payments
  10. Vericel Corporation $919 5 payments
  11. Other $1,767 21 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $426,349 53 payments
  2. Consulting Fee $314,729 106 payments
  3. Travel and Lodging $97,383 177 payments
  4. Grant $20,000 1 payment
  5. Food and Beverage $18,748 246 payments
  6. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $17,000 4 payments
  7. Education $16,155 6 payments
  8. Compensation for serving as faculty or as a speaker for a medical education program $5,500 2 payments
  9. Honoraria $1,000 1 payment
  10. Entertainment $19 1 payment
Products named General payments · program years 2019–2025
  1. SPATIAL FRAME $241,332 95 payments
  2. Bone Anchors with Arthroscopic Delivery System $116,579 52 payments
  3. BIOSURE $112,628 26 payments
  4. Q-FIX $94,072 34 payments
  5. NovoStitch $88,996 45 payments
  6. Bioinductive Implant with Arthroscopic Delivery System - Medium $67,753 30 payments
  7. CAP-FIX $61,428 31 payments
  8. HEALICOIL $43,575 30 payments
  9. NOVOSTITCH PRO $40,295 20 payments
  10. FAST-FIX 360 $38,663 8 payments
  11. Other $632,258 543 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

237

Median for Orthopedic Surgery: 203

Drug cost

$686

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Meloxicam Generic 204 $471
Gabapentin Generic 15 $120
Methylprednisolone Generic 18 $96

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 73 billing codes

Paid by Medicare

$137,378

Of which drugs: $14,242

Medicare patients

389

Average age 69

Services billed

5,634

258 women, 131 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 60%
Ischemic heart disease 20%
Diabetes 18%
Depression 17%
Osteoporosis 17%
Chronic kidney disease 12%
Cancer 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 41 3,920 $403
Injection, methylprednisolone acetate, 40 mg J1030 Office 18 40 $201

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

597 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record